An article published in the Journal of Translational Medicine on the 14th of August 2018, demonstrates the enhancing effect of IMM-101 on immune checkpoint inhibitors without added toxicity in four patients with advanced melanoma who had rapid and complete responses suggesting that IMM-101 may be activating a complementary pathway, which is synergistic with CPI treatment.

All four patients having received IMM-101 (either previously (n=3) or in combination with a checkpoint inhibitor (n=1)) were treated with checkpoint inhibitors and had rapid responses. One patient’s response commencing already 4 days after adding pembrolizumab. These data are supporting the company’s pre-clinical experiments of combining IMM-101 with immune checkpoint inhibitors. Such combination will be further explored in the company’s IMM-101-015 Phase II clinical trial. This open-label clinical study is expected to start soon and will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an anti-PD1 immune checkpoint inhibitor, in unresectable stage III or stage IV melanoma patients.

Full Title: Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity.

Authors: Angus G Dalgleish, Satvinder S Mudan and Alberto Fusi.